Advice

following a full submission assessed under the end of life and ultra-orphan processes

idelalisib (Zydelig®) is accepted for use within NHS Scotland.

Indication under review: Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Idelalisib demonstrated clinical activity, measured by overall response rate, in a phase II non-comparative study.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of idelalisib and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice192KB (PDF)

Download

Medicine details

Medicine name:
idelalisib (Zydelig)
SMC ID:
1039/15
Indication:
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published:
11 May 2015